The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer

Targeted Oncology

Volumn 10, Issue 2, 2015, Pages 235-245

  Smith, Donald L ^a   Acquaviva, Jaime ^a   Sequeira, Manuel ^a   Jimenez, John Paul ^a   Zhang, Chaohua ^a   Sang, Jim ^a   Bates, Richard C ^a   Proia, David A ^a  

^a Synta Pharmaceuticals Corp   (United States)

Author keywords

Combination therapy; Epidermal growth factor receptor; Ganetespib; HSP90 inhibitor; Non small cell lung cancer

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GANETESPIB; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MONOTHERAPY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; SCID MOUSE; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MICE, SCID; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS; TRIAZOLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930538007     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0329-6     Document Type: Article

References (48)

1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893–1907
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
3. Ramalingam S, Belani C (2008) Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13(Suppl 1):5–13
4. Grossi F, Kubota K, Cappuzzo F, de Marinis F, Gridelli C et al (2010) Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist 15:1102–1112
5. Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61:91–112
6. Gaughan EM, Costa DB (2011) Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 3:113–125
7. Herbst RS, Lynch TJ, Sandler AB (2009) Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 10:20–27
8. Stella GM, Luisetti M, Inghilleri S, Cemmi F, Scabini R et al (2012) Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. Respir Med 106:173–183
9. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR (2004) Clin Cancer Res 10:4227s–4232s
10. Ono M, Kuwano M (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12:7242–7251
11. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181
12. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792
13. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
14. Carrera S, Buque A, Azkona E, Aresti U, Calvo B et al (2014) Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Clin Transl Oncol 16:339–350
15. Jazieh AR, Al Sudairy R, Abu-Shraie N, Al Suwairi W, Ferwana M et al (2013) Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: a systematic review. Ann Thorac Med 8:204–208
16. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl 1):S24–31
17. Laurie SA, Goss GD (2013) Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Oncol 31:1061–1069
18. Gelsomino F, Agustoni F, Niger M, Valota M, Haspinger ER (2013) Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story. J Clin Oncol 31:3291–3293
19. Jassem J, Dziadziuszko R (2013) EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use? Lancet Oncol 14:916–917
20. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18:64–76
21. Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11:515–528
22. Reungwetwattana T, Dy GK (2013) Targeted therapies in development for non-small cell lung cancer. J Carcinog 12:22
23. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761–772
24. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537–549
25. Xu W, Neckers L (2007) Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13:1625–1629
26. Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15:9–14
27. Neckers L (2007) Heat shock protein 90: the cancer chaperone. J Biosci 32:517–530
28. Ying W, Du Z, Sun L, Foley KP, Proia DA et al (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11:475–484
29. Proia DA, Bates RC (2014) Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res 74:1294–1300
30. Proia DA, Sang J, He S, Smith DL, Sequeira M et al (2012) Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Investig New Drug 30:2201–2209
31. Acquaviva J, Smith DL, Sang J, Friedland JC, He S et al (2012) Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 11:2633–2643
32. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V et al (2013) A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19:3068–3077
33. Ramalingam S, Goss GD, Andric ZG, Bondarenko I, Zaric B, et al (2013) A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). J Clin Oncol 31:abstr CRA8007
34. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ et al (2012) Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 18:4973–4985
35. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342–350
36. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702–4711
37. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W et al (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:8686–8698
38. Sen B, Peng S, Tang X, Erickson HS, Galindo H et al (2012) Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med 4:136ra170
39. Shimamura T, Lowell AM, Engelman JA, Shapiro GI (2005) Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65:6401–6408
40. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E et al (2008) Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 68:5827–5838
41. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A et al (2012) Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 14:670–677
42. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA et al (2010) Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28:4953–4960
43. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26
44. Su KY, Chen HY, Li KC, Kuo ML, Yang JC et al (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30:433–440
45. Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K et al (2013) Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Cancer Sci 104:1346–1352
46. Johnson ML, Hart EM, Rademaker A, Weitner BB, Urman A, et al (2013) A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). J Clin Oncol 31:abstr 8036
47. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S et al (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14:981–988
48. Piperdi B, Perez-Soler R (2012) Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients. Drugs 72(Suppl 1):11–19